Showing results (51-60 of 58) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Leukemia & Lymphoma|June 22, 2022
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA studyHabte Yimer, Jason Melear, Edward Faber, et al.Blood|June 27, 2023
Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND studyDavid Belada, Katerina Kopeckova, Juan Miguel Bergua Burgues, et al.Targeted Oncology|October 23, 2021
Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL StudyEliza A Hawkes, Tycel Phillips, Lihua Elizabeth Budde, et al.NEJM Evidence|February 6, 2024
Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and ComorbiditiesArnon P Kater, Carolyn Owen, Carol Moreno, et al.Cancer|July 9, 2025
Talquetamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: Results from the phase 1/2 MonumenTAL-1 studyCarolina Schinke, Cyrille Touzeau, Albert Oriol, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2023
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW StudyTalha Munir, Carol Moreno, Carolyn Owen, et al.Blood Cancer Journal|April 21, 2022
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemiaKeith W Pratz, Panayiotis Panayiotidis, Christian Recher, et al.Nature Communications|February 6, 2024
A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndromeTerese C Hammond, Marco A Purbhoo, Sapana Kadel, et al.Pageof 6